Mundipharma acquires Middle East and Africa licensing and distribution rights for NTC's ophthalmology portfolio
DUBAI, United Arab Emirates, Dec. 12, 2017 /PRNewswire/ -- Mundipharma has expanded its ophthalmology portfolio in the Middle East and Africa by agreeing a new commercial partnership with NTC -- an Italian pharmaceutical company with deep experience in research and development -- to license and distribute a range of ophthalmic medicines in the region.
NTC's portfolio was developed to address unmet medical needs in the treatment of several ophthalmic diseases, including blepharitis, dry eye, allergies and glaucoma.
"The addition of the NTC medicines complements Mundipharma's current ophthalmology porfolio in the Middle East and Africa," said Mundipharma CEO, Raman Singh. "It's another bold and important step in our efforts to establish market leadership in the region backed by a strong and diversified portfolio of medicines."
As well as licensing and distribution rights, under the partnership Mundipharma will also benefit from NTC's commitment to research and development in ophthalmology.
NTC operates an international ophthalmology research and development program called Italian Innovation. Through the program, it engages with a large number of opinion leaders and clinical centres to focus on developing novel therapeutic solutions, with rich clinical insights, to offer to the scientific community tangible therapeutic evidence to unleash better and more affordable therapeutic treatments for patients.
"As NTC's strategic partner in Middle East and Africa, Mundipharma can now leverage its world class development and clinical programs to improve clinical outcomes in ophthalmology," added Mr Singh. "This is a great result for patients, who will benefit from improved access to more medicines with higher therapeutic value."
"Partnering with a leading company like Mundipharma is of real value and importance to NTC as it confirms the importance of our development efforts in the ophthalmic area," said Riccardo Carbucicchio, President and CEO, NTC.
"Mundipharma is an ideal strategic partner in the Middle East and Africa with the capability and expertise to extend the reach of these medicines to benefit more patients," he added.
About NTC Srl
NTC is a pharmaceutical company headquartered in Milan - Italy, with distributors and partners in over 70 countries in the world, engaged in research, development, registration and commercialization of drugs, medical devices and food supplements in ophthalmology, but also in other therapeutic areas like paediatrics and gastro-metabolism. NTC offers to its partners, currently above 200 companies, innovative pharmaceutical products with high quality standards. For more details, please see NTC's website (http://www.ntcpharma.com).
Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organisation that consistently delivers high quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: http://www.mundipharma.ae/
Upcoming Life Sciences Events
- October 2018
- Melbourne: Australia Biotech Invest & Partnering 2018
- South Brisbane: AusBiotech 2018
- November 2018
- Copenhagen: BIO-Europe 2018